• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

How About That Merck and Seattle Genetics Deal?

I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
By STEPHEN GUILFOYLE
Sep 14, 2020 | 10:30 AM EDT
Stocks quotes in this article: NVDA, ORCL, GILD, VZ, MRK, SGEN, PFE, MRNA, AZN

Of all of the deals announced this "Manic Monday", I think that maybe the one that I find the most interesting is the one that seems to be making the smallest ripples upon the pond. Obviously, the Nvidia (NVDA) deal for Arm Holdings is gigantic. Obviously, Oracle (ORCL) is top of the news this morning. Gilead Sciences (GILD) , and Verizon (VZ) all deserve the attention that the financial news services are giving them. But, and I mean but, did you kids catch that deal between Merck (MRK) and Seattle Genetics (SGEN) ? Just wow !!

Noticed This Late

I saw Merck move higher after the close on Friday night. The Wall Street Journal had reported late that the firm had started testing an experimental Covid-19 vaccine candidate on healthy human volunteers. I thought that great, but the fact is that Merck is approaching this problem differently than are some rivals such as Pfizer (PFE) , and Moderna (MRNA) that are using new, but unproven messenger RNA technology to race toward a useful vaccine. AstraZeneca (AZN) , another rival that is getting close, is using yet another technology known as a viral-vector based approach.

Merck is using a weakened version of the virus that causes Measles that it believes could deliver the spike protein that would trigger an immune response to Covid. Merck is enrolling just 260 patients in this trial (in Belgium) that is not projected to be completed until April 2022. In other words, Merck is going after a more complete, proven vaccine that maybe will not require booster shots. Long term potential usually does not drive stock performance after the closing bell on a Friday night. It wasn't this time either.

The Deal

Or should we say "deals"? There are apparently two rather complex deals between Merck and Seattle Genetics. First the larger, financially of the two. The two firms will globally develop and commercialize Ladiratuzumab Vedotin, which is an investigational antibody drug conjugate that Seattle Genetics has already been working on to target LIV-1 for breast cancer and various other solid tumors. The firms will evaluate this drug candidate as monotherapy, as well as in cocktail, or combination with Keytruda, which is Merck's anti PD-1 therapy meant for triple negative breast cancer, and other LIV-1 solid tumors.

The terms for this larger of two deals require that Seattle Genetics receive a $600 million upfront payment from Merck, as well as a $1 billion equity investment where Merck receives five million shares of common stock at $200 per. SGEN closed at $149.97 on Friday night. I see the shares were trading in the mid-$160's early in the pre-opening session. Seattle Genetics will then be eligible to receive in addition, progress-dependent milestone payments that could add up to another $2.6 billion. All told, if everything works like a charm, Merck ends up paying Seattle Genetics $4.2 billion over the course of this first of two deals.

The second of two deals grants Merck the exclusive licence to commercialize TUKYSA, which is a small molecule tyrosine kinase inhibitor, meant to fight HER2-positive cancers. The deal covers Asia, the Middle East, Latin America, and other areas exclusive of the U.S., Canada, and Europe. Seattle Genetics will retain commercial rights in these regions. For this license, Merck will pay $125 million upfront, up to $65 million in milestone payments and $85 million in prepaid research and development costs, as well as a tiered system of royalty payments in parts of the globe controlled under Merck by agreement.

Not Complaining

I am long Merck, not Seattle Genetics, though the one to own this morning is obviously SGEN. Merck, for me, is a solid well run pharmaceutical company run by an excellent CEO, Kenneth Frazier, that pays a steady dividend yielding 2.9%. Now, Merck's and Frazier's method of operations is always, in my opinion... well developed and aimed at longer-term strategies. The route that this firm took in the fight against Covid is proof in that pudding. This is why I am sure (as sure as a kid typing away in his own office could be) that this deal with Seattle Genetics is not half baked. Frazier saw growth and decided to pay for it. Very smart in this no-growth, cheap money environment. Jimmy Chill told us to buy SGEN a while back, didn't he? Probably should have listened. He saw the growth before anyone.

Investing

I will remain long MRK. The shares are trading at pivot ($85). My target price is $103. I intend to panic around $77. Have we missed the move in SGEN with the last sale at $165? Merck seems willing to pay $200 for a few more shares than I might buy. These shares were trading in the high $180's in late July. Not this morning, but soon, the next day that they hit the Health Care sector with vigor, I am going to have to buy some of these shares. Company does not make money. I'm thinking that changes.

(NVDA and SGEN are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long NVDA, VZ, MRK equity.

TAGS: Investing | Markets | Stocks | Trading

More from Investing

The Psilocybin Patent Race Is On

Debra Borchardt
Mar 6, 2021 12:30 PM EST

It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.

The Challenge of Short Selling

James "Rev Shark" DePorre
Mar 6, 2021 10:00 AM EST

Short selling is a powerful tool, but it is not just the inverse of going long and requires a very different mindset to do it effectively.

Kass: There Are Many Reasons to Be a Bear

Doug Kass
Mar 6, 2021 8:15 AM EST

I believe the markets are headed lower - probably not in a straight line or as steep as the last few days, but in a saw tooth fashion lower.

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

The Selloff in Twilio Could Extend Deeper Into March

Bruce Kamich
Mar 5, 2021 2:30 PM EST

TWLO could bounce in the short-run but avoid the long side for now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login